Ontario man says medication he's been taking for a decade just quadrupled in price
An Ontario man with Duchenne muscular dystrophy said he was shocked when he got his latest prescription filled for a medication he has been taking for the past ten years.
“I couldn’t believe it. I need to take this medication to help my muscles be able to work a bit better and it has almost quadrupled in price,” said 21-year-old Arun Crishanth of Aurora.
The medication is Deflazacort, a popular drug used to treat Duchenne muscular dystrophy, however it is not covered under government health plans.
The drug is a steroid taken daily to help keep muscles strong and symptoms of muscular dystrophy in check.
Crishanth said he used to get a four month supply of Deflazacort for $187, but when he got his last prescription filled it jumped to $666.
Crishanth was told by his pharmacy Pharmasave that the price increase was due to it being manufactured by a new drug company.
“This new company decided to turn around and quadruple the price. To me it seems ridiculous that they can increase the price that much," said Crishanth.
CTV News Toronto reached out to Pharmasave and a spokesperson said, “Pharmacy pricing in Canada is linked to the cost to purchase the medication from the manufacturer or distributor. The increased pricing experienced by pharmacies (and thus also to patients) is due to manufacturer and distributor changes.”
Deflazacort, a popular drug used to treat Duchenne muscular dystrophy, is photographed. CTV News Toronto also reached out to Muscular Dystrophy Canada and its CEO Stacey Lintern said in a statement, “Many individuals and their families have been advised by their doctors that Deflazacort is the most suitable option due to its minimal side effects, with some individuals having been on this treatment for 15 years or more. However, the significant increase in price will have detrimental effects on these individuals and their families.”
CTV News Toronto was unable to reach the new manufacturer of Deflazacourt, however Muscular Dystrophy Canada confirmed the price increase was due to a new manufacturer making the drug in Europe which also means increased shipping costs.
While there are cheaper alternatives, they have side effects and many patients with Duchenne muscular dystrophy feel that Deflazacourt is the preferred treatment.
"It’s a drug I’ve been taking for so many years, since I was 10 years old," said Crishanth, who said the drug will now cost him almost $2,000 a year.
"Obviously they should not be able to increase prices like that. It clearly isn't because of inflation, this is just to make some money and I think it's ridiculous that that can happen," said Crishanth.
Muscular Dystrophy Canada said it's important for patients to have equal access to appropriate treatments at a fair cost and that they will continue to try and influence change with regards to the price hike.
If you or your child is experiencing challenges accessing Deflazacort, you can contact Muscular Dystrophy Canada at research@muscle.ca or call 1-800-567-2873 ext. 1114.
CTVNews.ca Top Stories
Demand soars for solar eclipse glasses in Canada. Are they worth buying?
The demand for total solar eclipse glasses used to safely view the rare celestial event has been ramping up as sellers, along with astronomy and eye-care experts in Canada, warn that viewing the eclipse with the naked eye is dangerous.
'You ask for your money, they disappear': Ontario man loses $17K to AI crypto scam
A Toronto man is spreading the word of a cryptocurrency scam that lures victims using AI-generated news sites after he lost $17,000 in investments.
Hertz CEO out following electric car 'horror show'
The company, which announced in January it was selling 20,000 of the electric vehicles in its fleet, or about a third of the EVs it owned, is now replacing the CEO who helped build up that fleet, giving it the company’s fifth boss in just four years.
High thoughts: The habits of Canadian cannabis users are revealed in a new StatCan report
Statistics Canada has conducted a series of surveys to measure the impacts of legalized cannabis since the Cannabis Act took effect in 2018. The latest one, the 2023 National Cannabis Survey, sheds light on users' preferences and habits last year.
Trump says Jews who vote for Democrats 'hate Israel' and their religion
Former U.S. president Donald Trump on Monday charged that Jews who vote for Democrats 'hate Israel' and hate 'their religion,' igniting a firestorm of criticism from the White House and Jewish leaders.
Toronto family doctor who called patient's body 'perfect' suspended for 3 months: tribunal
A family doctor in Toronto has been suspended for three months after a disciplinary tribunal found that he failed to follow proper protocols while examining a patient's breasts and made inappropriate comments about her body.
Freddie Mercury's home is on the market for first time since 1980 minus his 'exquisite clutter'
Freddie Mercury's sanctuary in London, where he lived the last decade of his life, is on sale for the first time in nearly half a century -- minus his "exquisite clutter."
'The lost season': Winter comes to a close as Canada's warmest on record
The warmest winter on record could have far-reaching effects on everything from wildfire season to erosion, climatologists say, while offering a preview of what the season could resemble in the not-so-distant future unless steps are taken to cut greenhouse gas emissions.
Retired teacher pleads guilty to paying for sex with 15-year-old in Collingwood, Ont.
In a Barrie courtroom on Monday, a retired high school teacher from the Niagara Region pleaded guilty to sexual touching and obtaining sexual services from a 15-year-old boy in Collingwood in 2021.